Literature DB >> 15695027

[Brucellosis at the dawn of the 21st century].

M Maurin1.   

Abstract

Human brucellosis is now a rare disease in countries where eradication programs (especially vaccination) against brucellosis in cattle, sheep, and goats have been successfully implemented. In France, fewer than 50 brucellosis cases are annually notified to the National Institute for Infection Surveillance. Human brucellosis, however, remains endemic in the Mediterranean basin, Middle East, Western Asia, Africa, and South America. Shortcomings of standard diagnostic methods for brucellosis (variable sensitivity of culture, frequent serological cross reactions) have been only partially resolved by modern molecular biology techniques. There are now 3 new challenges to be faced by the medical and veterinarian community: the expanding wildlife reservoir of brucellosis, with a possible impact on domestic animals; the emergence of Brucella. melitensis infections in cattle, for which prophylactic efficacy of available vaccines has not been established; and recent recognition of a huge animal reservoir of Brucella species in marine mammals, for which the potential virulence in humans remains unknown.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695027     DOI: 10.1016/j.medmal.2004.08.003

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  10 in total

1.  Brucellosis seroprevalence in livestock in Uganda from 1998 to 2008: a retrospective study.

Authors:  Robert Mwebe; Jesca Nakavuma; Ignacio Moriyón
Journal:  Trop Anim Health Prod       Date:  2010-11-17       Impact factor: 1.559

2.  A comparative study of the seroprevalence of brucellosis in commercial and small-scale mixed dairy-beef cattle enterprises of Lusaka province and Chibombo district, Zambia.

Authors:  Henry M Chimana; John Bwalya Muma; Kenny L Samui; Benard M Hangombe; Musso Munyeme; Gift Matope; Andrew M Phiri; Jacques Godfroid; Eystein Skjerve; Morten Tryland
Journal:  Trop Anim Health Prod       Date:  2010-06-03       Impact factor: 1.559

3.  Exploring the Diversity of Field Strains of Brucella abortus Biovar 3 Isolated in West Africa.

Authors:  Moussa Sanogo; David Fretin; Eric Thys; Claude Saegerman
Journal:  Front Microbiol       Date:  2017-06-30       Impact factor: 5.640

4.  Complete Genome Sequencing of 10 Brucella abortus Biovar 3 Strains Isolated from Water Buffalo.

Authors:  Rubina Paradiso; Massimiliano Orsini; Daniela Criscuolo; Rosanna Borrelli; Ornella Valvini; Cesare Cammà; Maria Luisa Chiusano; Giorgio Galiero; Giorgia Borriello
Journal:  Genome Announc       Date:  2018-04-19

5.  Risk factors for human brucellosis among a pastoralist community in South-West Kenya, 2015.

Authors:  Mathew Muturi; Austine Bitek; Athman Mwatondo; Eric Osoro; Doris Marwanga; Zeinab Gura; Phillip Ngere; Zipporah Nganga; S M Thumbi; Kariuki Njenga
Journal:  BMC Res Notes       Date:  2018-12-05

6.  First case-control study of zoonotic brucellosis in Gafsa district, Southwest Tunisia.

Authors:  Médiha Khamassi Khbou; Samaher Htira; Kaouther Harabech; M'hammed Benzarti
Journal:  One Health       Date:  2017-12-19

7.  Pancytopenia revealing acute brucellosis.

Authors:  Yassine Ben Lahlou; Elmostafa Benaissa; Adil Maleb; Mariama Chadli; Mostafa Elouennass
Journal:  IDCases       Date:  2020-12-29

8.  Clinical Presentations of Brucellosis Over a Four-Year Period at Sultan Qaboos University Hospital and Armed Forces Hospital, Muscat, Oman.

Authors:  Kowthar S Hassan; Helmut Schuster; Abdullah Al-Rawahi; Abdullah Balkhair
Journal:  Sultan Qaboos Univ Med J       Date:  2021-06-21

9.  [Neurobrucellosis: a treatable cause of sensorineural hearing loss not to ignore].

Authors:  Alae Bezzari Malhi; Mohamed Ridal; Siham Bouchal; Mohammed Faouzi Belahsen; Mohamed-Nourdine El Alami
Journal:  Pan Afr Med J       Date:  2015-10-12

10.  Brucellosis in wildlife in Africa: a systematic review and meta-analysis.

Authors:  Gregory Simpson; Peter N Thompson; Claude Saegerman; Tanguy Marcotty; Jean-Jacques Letesson; Xavier de Bolle; Jacques Godfroid
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.